Patterns of Cancer Progression of Metastatic Hormone-sensitive Prostate Cancer in the ECOG3805 CHAARTED Trial-Reference-Cited by-同舟云学术

Patterns of Cancer Progression of Metastatic Hormone-sensitive Prostate Cancer in the ECOG3805 CHAARTED Trial

Published:2020-12 Issue:6 Volume:3 Page:717-724
ISSN:2588-9311
Container-title:European Urology Oncology
language:en
Short-container-title:European Urology Oncology

Author:

Bryce Alan H.^ORCID,Chen Yu Hui,Liu Glenn,Carducci Michael A.,Jarrard David M.,Garcia Jorge A.,Dreicer Robert,Hussain Maha,Eisenberger Mario Alfredo,Plimack Elizabeth R.,Vogelzang Nicholas J.,DiPaola Robert S.,Harshman Lauren,Sweeney Christopher J.

Funder

NCI

Publisher

Elsevier BV

Subject

Urology,Radiology Nuclear Medicine and imaging,Oncology,Surgery

Reference19 articles.

1. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer;Sweeney;N Engl J Med,2015

2. Burden of metastatic castrate naive prostate cancer patients, to identify men more likely to benefit from early docetaxel: further analyses of CHAARTED and GETUG-AFU15 studies;Gravis;Eur Urol,2018

3. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial;Kyriakopoulos;J Clin Oncol,2018

4. Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer;Chi;N Engl J Med,2019

5. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer;Fizazi;N Engl J Med,2017

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. GDF15 propeptide promotes bone metastasis of castration-resistant prostate cancer by augmenting the bone microenvironment;2024-09-08

2. Antiandrogen Withdrawal Syndrome After Discontinuation of Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer: A Report of Two Clinical Cases and a Literature Review;Cureus;2024-06-30

3. Evaluating prostate cancer bone metastases response with whole-body MRI: What we know and still need to know;European Radiology;2024-06-20

4. Radiographic Progression Without Corresponding Prostate-specific Antigen Progression in Patients with Metastatic Castration-sensitive Prostate Cancer Receiving Apalutamide: Secondary Analysis of the TITAN Trial;European Urology Oncology;2024-04

5. Feasibility of Monitoring Response to Metastatic Prostate Cancer Treatment with a Methylation-Based Circulating Tumor DNA Approach;Cancers;2024-01-23